Compare · CI vs DGX
CI vs DGX
Side-by-side comparison of The Cigna Group (CI) and Quest Diagnostics Incorporated (DGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and DGX operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.58B, about 3.6x DGX ($21.50B).
- Over the past year, CI is down 13.2% and DGX is up 9.8% - DGX leads by 23.0 points.
- CI has been more active in the news (18 items in the past 4 weeks vs 15 for DGX).
- Both have 25 recent analyst ratings on file.
- Company
- The Cigna Group
- Quest Diagnostics Incorporated
- Price
- $290.66-0.61%
- $194.50+2.83%
- Market cap
- $76.58B
- $21.50B
- 1M return
- +8.98%
- -0.78%
- 1Y return
- -13.22%
- +9.78%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 18
- 15
- Recent ratings
- 25
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest CI
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- The Cigna Group Reports Strong First Quarter 2026 Results, Raises 2026 Outlook
- The Cigna Group filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
Latest DGX
- SEC Form FWP filed by Quest Diagnostics Incorporated
- Quest Diagnostics Prices $500 Million of Senior Notes
- Executive Vice President & CFO Samad Sam was granted 108 shares, increasing direct ownership by 0.32% to 33,376 units (SEC Form 4)
- SVP for Diagnostic Services Plewman Patrick increased direct ownership by 0.32% to 15,247 units (SEC Form 4)
- Director Gregg Vicky B was granted 68 shares, increasing direct ownership by 0.40% to 17,172 units (SEC Form 4)
- Director Carter Robert B increased direct ownership by 0.26% to 2,711 units (SEC Form 4)
- Director Lassiter Wright Iii increased direct ownership by 0.07% to 9,063 units (SEC Form 4)
- SVP, Clinical Solutions Kuppusamy Karthik increased direct ownership by 0.29% to 13,490 units (SEC Form 4)
- SVP & Chief Commercial Officer Delaney Mark E increased direct ownership by 0.31% to 11,901 units (SEC Form 4)
- SEC Form 10-Q filed by Quest Diagnostics Incorporated